Health Trials

Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial

ConditionsNeuroendocrine TumorsNeuroendocrine Tumor Grade 1Neuroendocrine Tumor Grade 2Neuroendocrine Neoplasm
Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorThe Netherlands Cancer Institute

About this trial

According to current guidelines, patients have to withhalt long-acting somatostatin analogues (LA-SSA) for 4-6 weeks prior to every 177Lutetium-DOTATATE administration. The primary objective of the study is to investigate the effect of LA-SSA on the absorbed dose in tumor lesions during PRRT.

Eligibility criteria

Qualifiers

Age ≥ 18 years;

Able to provide spoken and written informed consent for the trial;

Histopathological confirmed neuroendocrine tumor;

Fulfill the clinical criteria for PRRT;

Disqualifiers

Not possible to discontinue LA-SSA for 4-6 weeks;

Use of short-acting SSAs;

Pregnancy and lactating female patients;

Inability to comply to the study procedures;

Trial design

Treatments tested in this trial

  • Somatostatin analog

Treatment groups

39 Participants
are divided into 3 treatment groups

Sponsors and collaborators

The Netherlands Cancer Institute

Lead sponsor

Neuroendocrine Tumor Research Foundation

Collaborator

Source ClinicalTrials.gov